Bionano Genomics, Inc. (BNGO) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.14
↓-88% vs avg
5yr avg: 1.21
30Y Low0.1·High9.3
ROE
↓
-66.2%
↓+27% vs avg
5yr avg: -91.0%
30Y Low-434%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BNGO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bionano Genomics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $8M | $33M | $66M | $431M | $844M | $328M | $315456 | $631942 | — | — |
| Enterprise Value | $8M | $12M | $51M | $127M | $437M | $830M | $305M | $3M | $-6861413 | — | — |
| P/E Ratio → | -0.24 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.13 | 0.29 | 1.07 | 1.82 | 15.49 | 46.95 | 38.52 | 0.03 | 0.05 | — | — |
| P/B Ratio | 0.14 | 0.19 | 0.93 | 0.68 | 1.73 | 2.50 | 9.34 | 0.09 | 0.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BNGO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.43 | 1.66 | 3.52 | 15.73 | 46.17 | 35.92 | 0.30 | -0.57 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BNGO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bionano Genomics, Inc. earns an operating margin of -116.9%. Operating margins have expanded from -596.0% to -116.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -66.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.0% | 22.0% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% | 36.6% | 47.3% |
| Operating Margin | -116.9% | -116.9% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | -244.3% | -311.6% |
| Net Profit Margin | -92.6% | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% | -277.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.2% | -66.2% | -170.3% | -134.6% | -45.2% | -38.9% | -212.5% | -433.6% | -182.5% | — | — |
| ROA | -35.1% | -35.1% | -77.0% | -89.1% | -38.7% | -33.1% | -90.7% | -108.4% | -105.9% | -187.4% | -127.5% |
| ROIC | -49.1% | -49.1% | -73.9% | -78.1% | -34.1% | -34.4% | -298.9% | -429.8% | -579.1% | — | — |
| ROCE | -74.1% | -74.1% | -135.3% | -111.5% | -42.0% | -37.9% | -139.3% | -214.5% | -296.5% | — | -390.3% |
BNGO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($7M total debt minus $3M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.77 | 0.83 | 0.05 | 0.03 | 0.47 | 5.56 | 0.89 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.09 | 0.51 | 0.64 | 0.03 | -0.04 | -0.63 | 0.77 | -0.74 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -111.88 | -111.88 | -386.49 | -44.41 | -437.63 | -83.31 | -14.71 | -12.03 | -12.38 | -38.51 | -39.07 |
BNGO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.98x means Bionano Genomics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.40x to 1.98x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 | 5.23 | 1.07 | 5.09 | 0.43 | 1.15 |
| Quick Ratio | 1.74 | 1.74 | 0.76 | 1.17 | 3.55 | 11.91 | 4.86 | 0.94 | 4.85 | 0.33 | 0.95 |
| Cash Ratio | 0.58 | 0.58 | 0.25 | 0.67 | 3.15 | 11.47 | 4.30 | 0.66 | 3.65 | 0.06 | 0.56 |
| Asset Turnover | — | 0.39 | 0.40 | 0.17 | 0.09 | 0.05 | 0.14 | 0.34 | 0.48 | 0.94 | 0.46 |
| Inventory Turnover | 4.08 | 4.08 | 2.73 | 1.16 | 0.73 | 1.14 | 1.73 | 1.97 | 8.15 | 3.56 | 1.99 |
| Days Sales Outstanding | — | 66.58 | 56.62 | 97.64 | 98.41 | 108.01 | 119.12 | 228.23 | 137.30 | 128.73 | 99.22 |
BNGO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bionano Genomics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $2M | $580551 | $491658 | $470530 | $177227 | $424 | $201 | $0 | $0 |
Peer Comparison
Compare BNGO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BNGOYou | $4M | -0.2 | — | — | 22.0% | -116.9% | -66.2% | -49.1% | — |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
 CDNA | $1B | -65.5 | — | 37.4 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 NTRA | $33B | -152.2 | — | 303.7 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 VCYT | $4B | 65.4 | 41.4 | 33.8 | 69.6% | 14.3% | 5.3% | 5.6% | 0.4 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 A | $36B | 27.8 | 21.2 | 31.2 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
 BIO | $8B | 10.1 | 18.1 | 20.4 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BNGO — Frequently Asked Questions
Quick answers to the most common questions about buying BNGO stock.
What is Bionano Genomics, Inc.'s P/E ratio?
Bionano Genomics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is Bionano Genomics, Inc.'s ROE?
Bionano Genomics, Inc.'s return on equity (ROE) is -66.2%. The historical average is -160.5%.
Is BNGO stock overvalued?
Based on historical data, Bionano Genomics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Bionano Genomics, Inc.'s profit margins?
Bionano Genomics, Inc. has 22.0% gross margin and -116.9% operating margin.